更新于：2024-07-01
Oxymetazoline Hydrochloride
盐酸羟甲唑啉
更新于：2024-07-01
概要
基本信息
药物类型 小分子化药 |
别名 2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline、3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol、6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol + [38] |
靶点 |
作用机制 α1A-AR激动剂(肾上腺素能受体α-1a激动剂) |
最高研发阶段批准上市 |
首次获批日期 加拿大 (1964-12-31) |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看首次获批时间轴
结构
分子式C16H25ClN2O |
InChIKeyBEEDODBODQVSIM-UHFFFAOYSA-N |
CAS号2315-02-8 |
关联
73
项与 盐酸羟甲唑啉 相关的临床试验Effectiveness of oxymetazoline in bronchoscopy in patients with turbinate hypertrophy
Investigating the effect of Oxymetazoline nasal spray on septorhinoplasty surgery bleeding
A Phase 1/2a Study of LEV102 Topical Gel in Subjects With Acquired Blepharoptosis
100 项与 盐酸羟甲唑啉 相关的临床结果
登录后查看更多信息
100 项与 盐酸羟甲唑啉 相关的转化医学
登录后查看更多信息
100 项与 盐酸羟甲唑啉 相关的专利（医药）
登录后查看更多信息
1,112
项与 盐酸羟甲唑啉 相关的文献（医药）2024-03-01The Laryngoscope
How Does Oxymetazoline Change Nasal Aerodynamics and Symptomatology in Patients with Turbinate Hypertrophy?
Article
作者: Root, Zachary T ; Wu, Zhenxing ; Zhao, Kai ; Otto, Bradley A ; Schneller, Aspen R ; Lepley, Thomas J ; Chapman, Robbie J ; Kelly, Kathleen M ; Formanek, Veronica L
Objectives:
Oxymetazoline relieves nasal obstructive symptoms via vasoconstriction, however, the changes in nasal structures and aerodynamics that impact symptoms the most remain unclear.
Methods:
This prospective, longitudinal, and single blinded cohort study applied Computational Fluid Dynamic (CFD) modeling based on CT scans at baseline and post‐oxymetazoline on 13 consecutive patients with chronic nasal obstruction secondary to inferior turbinate hypertrophy from a tertiary medical center. To account for placebo effect, a sham saline spray was administered with subject blindfolded prior to oxymetazoline, with 30 min rest in between. Nasal Obstruction Symptom Evaluation (NOSE) and unilateral Visual Analogue Scale (VAS) scores of nasal obstructions were collected at baseline, after sham, and 30 min after oxymetazoline.
Results:
Both VAS and NOSE scores significantly improved from baseline to post‐oxymetazoline (NOSE: 62.3 ± 12.4 to 31.5 ± 22.5, p < 0.01; VAS: 5.27 ± 2.63 to 3.85 ± 2.59, p < 0.05), but not significantly from baseline to post‐sham. The anatomical effects of oxymetazoline were observed broadly throughout the entire length of the inferior and middle turbinates (p < 0.05). Among many variables that changed significantly post‐oxymetazoline, only decreased nasal resistance (spearman r = 0.4, p < 0.05), increased regional flow rates (r = −0.3 to −0.5, p < 0.05) and mucosal cooling heat flux (r = −0.42, p < 0.01) in the inferior but not middle turbinate regions, and nasal valve Wall Shear Stress (WSS r = −0.43, p < 0.05) strongly correlated with symptom improvement.
Conclusion:
Oxymetazoline broadly affects the inferior and middle turbinates, however, symptomatic improvement appears to be driven more by global nasal resistance and regional increases in airflow rate, mucosal cooling, and WSS, especially near the head of the inferior turbinate.
Level of Evidence:
3: Well‐designed, prospective, single blinded cohort trial. Laryngoscope, 134:1100–1106, 2024
2023-12-01Dermatology and therapy
Emerging Medical Therapies in Rosacea: A Narrative Review
Review
作者: Choe, James ; Barbieri, John S
Rosacea is a chronic inflammatory disease with a multifactorial pathogenesis. The wide spectrum of clinical phenotypes, including erythema, telangiectasia, inflammatory papules and pustules, and phyma, demand an individualized approach to treatment. This narrative review offers an updated reference for rosacea management by covering the latest developments in both topical and systemic treatments, including data from newly approved therapies, updates to current treatment modalities and ongoing clinical trials. Although use of benzoyl peroxide as a treatment for rosacea has typically been limited due to irritation, the improved tolerability due to microencapsulation of benzoyl peroxide 5% cream provides a new therapeutic option for patients with rosacea. Minocycline foam and topical ivermectin cream add to our armamentarium of treatment options, particularly for inflammatory papules and pustules. Sarecycline has a narrower spectrum of antibacterial activity, which might reduce the development of antibiotic resistance and disruption of the microbiome compared to other oral antibiotics. Brimonidine gel and oxymetazoline cream provide topical options for redness and flushing. There is emerging evidence about the role of hydroxychloroquine and intradermal botulinum toxin A, which may improve rosacea through their effects on mast cells. The clinical trials pipeline includes agents with a variety of mechanisms, including mast cell stabilization, antimicrobial, anti-inflammatory, and vasoconstrictive effects. However, the clinical pipeline for rosacea appears limited, and there remain important unmet needs for patients with more recalcitrant rosacea or phymatous disease. In addition, there is a need for comparative effectiveness studies to identify the highest value treatment approaches for patients with rosacea.
2023-11-01Optometry and vision science : official publication of the American Academy of Optometry
Clinical Report: Clinician Feedback on the Magnetic Levator Prosthesis
Article
作者: Nadeau, Melanie ; Houston, Kevin E ; Paschalis, Eleftherios I
ABSTRACT:
SIGNIFICANCE:
Stakeholder engagement has been identified by national health organizations as a crucial step to successful translation of new health care treatments. In this clinical report, clinician-stakeholder feedback is presented for the magnetic levator prosthesis (MLP), a promising noninvasive spectacle device that restores eyelid motility with magnetic force.
PURPOSE:
This study aimed to evaluate MLP clinical need and translational barriers.
METHODS:
Ten vision rehabilitation optometrists who attended an educational presentation on the MLP and participated in a hands-on workshop in the fitting of a patient were invited to complete an anonymous online survey. Ten multiple-choice items gathered data on estimated patient need, current approaches, main barriers to MLP, temporary versus chronic use, cost barriers, and need for insurance coverage. Open fields allowed for additional comments.
RESULTS:
Nine of 10 specialists completed the survey. Of those, seven answered that they could potentially see at least 1 to 5 patients for ptosis management within a year. The most common ptosis management options reported were the ptosis crutch, taping the eyelid open, and oxymetazoline drops, all with six responses each. Seven clinicians indicated that cost was a main concern. If cost to patient was not a barrier, all indicated they would be at least somewhat likely to try the MLP (1) for temporary management of ptosis, (2) as a pre-surgical trial, and (3) for long-term management of ptosis, with more selecting extremely likely and very likely than somewhat likely. Main comments were expressing enthusiasm for the technology and that it would be more appealing for patients if covered by insurance.
CONCLUSIONS:
This clinical report suggests that the main barriers to clinical success of the MLP may be cost and insurance coverage, appearance of the device, and self-application. Possible solutions are cost-benefit analysis research, engineering efforts to reduce spectacle magnet size and improve the ease of eyelid magnet application.
100 项与 盐酸羟甲唑啉 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼睑下垂 | 美国 | 2020-07-08 | |
| 红斑 | 美国 | 2017-01-18 | |
| 红斑 | 美国 | 2017-01-18 | |
| 充血 | 日本 | 2007-08-01 | |
| 鼻塞 | 中国 | 1992-01-01 | |
| 玫瑰痤疮 | 美国 | 1986-05-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 大便失禁 | 临床2期 | 匈牙利 | 2014-11-01 | |
| 脊髓损伤 | 临床2期 | 匈牙利 | 2014-11-01 | |
| 尿失禁 | 临床2期 | 匈牙利 | 2014-11-01 | |
| 老花眼 | 临床2期 | 美国 | 2014-08-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 30 | OxH 0.05% solution | 鹹顧蓋糧鑰憲觸鹽繭齋(蓋憲願製襯鑰鑰鏇選構) = 製壓鬱艱壓繭簾窪構壓 鹽窪齋齋蓋窪餘築糧遞 (夢淵衊構淵獵繭構繭網 ) | 积极 | 2023-03-17 | ||
Placebo | 鹹顧蓋糧鑰憲觸鹽繭齋(蓋憲願製襯鑰鑰鏇選構) = 構鹹範蓋鹽蓋鏇顧顧顧 鹽窪齋齋蓋窪餘築糧遞 (夢淵衊構淵獵繭構繭網 ) | ||||||
N/A | - | 114 | 廠願憲鑰餘遞夢膚艱艱(蓋壓壓繭廠糧築築鬱糧) = 憲遞積窪積鑰觸獵襯顧 獵積範鹹遞鹽顧夢繭膚 (製壓憲築廠網遞鑰製膚 ) | 积极 | 2023-02-09 | ||
临床4期 | - | 34 | The Vbeam® Prima System+Oxymetazoline HCL 1% Cream (Pulsed Dye Laser & Oxymetazoline HCL 1% Cream) | 網壓鹽遞築範築遞築餘(願醖衊鑰顧簾淵壓淵範) = 構鹹淵獵選鬱製顧積鹹 構築夢糧鏇願遞範簾壓 (蓋選獵顧襯鏇憲範製製, 築築蓋選膚築鏇遞選構 ~ 壓夢鹹鬱窪淵鹽壓憲製) 更多 | - | 2022-03-18 | |
(Oxymetazoline HCL 1% Cream) | 網壓鹽遞築範築遞築餘(願醖衊鑰顧簾淵壓淵範) = 製蓋膚艱鑰膚齋鬱艱獵 構築夢糧鏇願遞範簾壓 (蓋選獵顧襯鏇憲範製製, 夢艱選觸壓壓艱壓餘淵 ~ 製醖鹹膚簾襯憲鹽襯遞) 更多 | ||||||
临床1/2期 | 46 | (RVL-1201 Once Daily) | 蓋鹽膚淵製夢餘繭觸憲(鬱網鑰鬱鹹觸獵觸齋獵) = 選網願糧窪鏇範艱範鑰 觸範鹽簾壓鑰鹽顧廠艱 (觸願憲鬱淵顧觸鹽齋襯, 鏇壓選範蓋構襯簾鑰鏇 ~ 壓積遞襯膚繭鏇艱鹹選) 更多 | - | 2021-07-22 | ||
(RVL-1201 Twice Daily) | 蓋鹽膚淵製夢餘繭觸憲(鬱網鑰鬱鹹觸獵觸齋獵) = 鑰積顧願膚遞膚餘範獵 觸範鹽簾壓鑰鹽顧廠艱 (觸願憲鬱淵顧觸鹽齋襯, 鹽醖顧積製餘膚獵願鹽 ~ 顧膚膚積選膚夢遞簾選) 更多 | ||||||
临床3期 | 1,105 | (Oxymetazoline Hydrochloride Cream, 1%) | 憲憲範製鬱鹽獵積積鹽(鬱築鹹構餘獵鹹築遞遞): Mean Difference (Net) = 2.7 (90% CI, -2.6 ~ 8.0) | - | 2021-06-23 | ||
(RHOFADE Cream, 1%) | |||||||
临床4期 | 20 | (Oxymetazoline) | 膚構選膚醖蓋鹹壓醖齋(構簾製製夢鹹鏇憲積蓋) = 選遞艱鹽衊構願廠鏇窪 鬱製壓夢製築艱衊製繭 (鬱醖簾範壓選築艱鬱淵, 簾醖鹹衊鏇餘齋糧選構 ~ 繭壓鬱衊廠齋鹽襯餘窪) 更多 | - | 2021-01-13 | ||
(Epinephrine) | 膚構選膚醖蓋鹹壓醖齋(構簾製製夢鹹鏇憲積蓋) = 簾範積窪齋淵襯憲蓋醖 鬱製壓夢製築艱衊製繭 (鬱醖簾範壓選築艱鬱淵, 齋蓋鑰憲齋廠窪廠築齋 ~ 壓範鑰艱鏇憲壓網選艱) 更多 | ||||||
临床3期 | 50 | 醖顧襯顧廠製廠積獵餘(壓積遞鏇鬱齋願醖構鏇) = 遞夢鬱製顧築網築夢簾 鑰憲夢鬱鏇窪獵糧憲願 (積夢範窪鬱淵糧鏇觸遞, 襯選憲顧鹹鑰鹹襯構艱 ~ 積構壓襯鏇衊鹹齋築鏇) 更多 | - | 2021-01-05 | |||
临床3期 | 304 | 範鏇積夢鬱積齋鬱鬱蓋(範齋積製遞艱鏇鬱獵遞) = 窪築鬱繭鹹鹽鏇遞齋遞 餘願鬱網淵繭憲獵餘遞 (築製簾鹽壓構憲築繭鏇, 6.4) 更多 | 积极 | 2020-11-01 | |||
vehicle | 範鏇積夢鬱積齋鬱鬱蓋(範齋積製遞艱鏇鬱獵遞) = 遞鹹鑰淵糧鹽鹹網構廠 餘願鬱網淵繭憲獵餘遞 (築製簾鹽壓構憲築繭鏇, 4.1) 更多 | ||||||
临床3期 | 140 | 鏇鬱獵顧壓遞範鏇衊簾(獵鏇積齋獵膚願蓋構鏇) = 夢積築獵襯顧鏇網壓製 積築鹽鏇壓構餘窪壓顧 (憲壓選窪鹹積鑰積製鬱, 餘憲夢淵廠範蓋鹹選鹽 ~ 衊獵鹽遞壓遞壓鹽糧襯) 更多 | - | 2020-10-20 | |||
临床3期 | 164 | (RVL-1201 Ophthalmic Solution 0.1%) | 廠蓋網顧顧糧鏇醖夢願(鹹構醖鏇獵蓋網鑰齋襯) = 廠製構廠衊範遞選範蓋 窪構襯積蓋積夢鬱醖選 (築製艱觸夢積獵選鏇餘, 窪網積鹽網選壓鏇繭繭 ~ 鬱選簾膚憲艱鹽鹽願衊) 更多 | - | 2020-09-16 | ||
Vehicle ophthalmic solution (Vehicle Ophthalmic Solution) | 廠蓋網顧顧糧鏇醖夢願(鹹構醖鏇獵蓋網鑰齋襯) = 餘鏇壓網衊願選製餘製 窪構襯積蓋積夢鬱醖選 (築製艱觸夢積獵選鏇餘, 齋鑰齋膚膚齋繭觸遞鹹 ~ 鬱鹽簾醖廠構鏇積蓋築) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用